We conducted a prospective cohort study to determine whether administration of large doses of the corticosteroid methylprednisolone following spinal cord injury as recommended in the National Acute Spinal Cord Injury Study-2 (NASCIS-2) protocol results in an increased incidence of avascular necrosis (AVN) of the femoral or humeral head. All subjects were patients treated by a spinal cord injury physician in an Acute Spinal Cord Injury Unit between 1989 and 1996 where some received the megadose steroids while others did not. Patients younger than 15 years and older than 75 years were excluded, as were those with any hip or shoulder disease, with pelvic fracture, or with a history of predisposition to AVN by hip dislocation, excessive alcohol consumption, previous high dose steroid use, or systemic lupus erythematosus. Screening for AVN of the femoral and humeral heads was performed at a minimum of 6 months following injury, using magnetic resonance imaging (MRI). The ®lms were read by a radiologist blinded to the treatment protocol received by the individual subject. Among the 59 spinal cord injured patients who received steroids (age 15 ± 64 years (mean 32 years)), ®ve were female. Among the 32 spinal cord injured subjects who did not receive steroids (age 16 to 65 years (mean 34 years)), seven were female. There was no case of AVN found in either group. Using binomial distribution, we conclude that the true incidence of AVN among the methylprednisolone treated group is less than 5% (a50.05) and therefore continue to recommend short term (24 h) methylprednisolone therapy.
Introduction
Steroids have long been known to improve the neurological outcome of experimental spinal cord injuries in animal studies. 1 As a result, many spinal cord injury units around the world routinely administered moderate dose steroids to all patients suering spinal cord injuries, but subsequent clinical studies failed to show any bene®t. 2, 3 In order to demonstrate the ineectiveness of corticosteroids, a randomized controlled study was conducted by the National Acute Spinal Cord Injury Study group (NASCIS-1). 4 The treatment group received a 1000 mg bolus of methylprednisolone (Mpred) with 1000 mg daily for 10 days, while the control group was given a 100 mg bolus with 100 mg daily for 10 days. There was no signi®cant dierence in neurologic outcome between the two groups.
Most of the studies of steroids in the clinical setting did not take into consideration the pharmacodynamics and pharmacokinetics of corticosteroids which likely were responsible for the dierence between human and animal study results. 2, 3 Clinical studies administered Mpred at 0.6 ± 30 mg kg 71 within 24 h of injury, while animal studies used 15 ± 30 mg kg 71 within 1 ± 4 h of injury.
A second randomized, controlled, double-blind study was carried out (NASCIS-2) where the control group was given a placebo, the ®rst treatment group received a naloxone 5.4 mg kg 71 bolus with a 4 mg kg 71 hr 71 infusion for 23 h, and, a second treatment group received a 30 mg kg 71 bolus followed by a 5.4 mg kg 71 hr 71 Mpred intravenous infusion for 23 h. 5, 6 Treatment was instituted within 12 h of injury. Subjects who received Mpred within 8 h of injury showed signi®cant improvement in neurologic outcome at 6 months post-injury compared to both the control and naloxone groups, whereas there was no dierence between the control and the naloxone groups. Based on the results of this study, the majority of spinal cord injury units, including our own, now routinely follow the NAS-CIS-2 high-dose Mpred protocol for all spinal cord injured patients.
Following this protocol adult patients weighing 55 ± 80 kg would receive between 11 000 mg and 15 000 mg of Mpred over 24 h. Concern about these extremely high dosages caused the NASCIS-2 study group to assess the incidence of steroid-related adverse eects including wound infection, gastrointestinal bleeding, liver enzymes, and`other complications'. However, there was no assessment of the potential for avascular necrosis (AVN) of the femoral or humeral head leading to hip and shoulder joint destruction, degeneration, and ultimately hip or shoulder joint replacement. In spinal cord injured young people who are dependent upon their shoulders for their mobility, or who place additional stress on their hips because of an abnormal gait, avascular necrosis could be devastating.
Saisu recently reported a 27% incidence rate of osteonecrosis of the femoral head in renal transport patients receiving 0 mg to 4000 mg corticosteroid therapy and a 100% rate in those receiving more than 4000 mg (total intravenous sustained and pulse dose) of Mpred (equivalents) in the ®rst three months post transplant. 7 Similarly, Marsh reported a 21% incidence of AVN in patients treated for aplastic anaemia with antilymphocyte globulin (ALG) followed by 5 mg/kg/day doses of Mpred (to treat the consequent serum sickness) in contrast to a 0% incidence using 1 mg/kg/day dosages. 8 Patients in the Marsh study were treated for 5 days with ALG and between 2 ± 4 weeks with Mpred. Continuous high-dose Mpred treatment was also found to be a risk factor for AVN in the treatment of systemic lupus erythematosus. 9, 10 Several case reports have shown humeral and femoral AVN resulting from short term, high dosage steroid treatments (520 ± 3400 mg over 7 to 32 days).
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Felson and Anderson's metaanalysis of 22 previous AVN incidence studies comparing steroid dose and bolus steroids indicated that a 9000 mg prednisone (equivalent) cumulative dosage given in a month had a 22% incidence of AVN. 17 To investigate whether the NASCIS-2 Mpred protocol results in an increased incidence of AVN of the femoral or humeral head within 12 months of injury, we conducted a prospective cohort study of patients treated at two centres between 1989 and 1996.
Method
Potential subjects for the study were those patients with con®rmed neurologic de®cit ( 5 while others treated before the publication of the NASCIS-2 study or presenting more than 8 h post injury did not receive steroids.
Patients were excluded from the study if they had a factor likely to result in a false positive MRI scan: were younger than 15 years (to ensure closure of femoral capital epiphysis); or older than 75 years (advanced joint destruction due to aging); had any hip or shoulder disease with radiologic abnormality; or pelvic fracture. Patients were also excluded if they had a history predisposing to AVN, including hip dislocation, excessive alcohol consumption, previous high-dose steroid use (including sports related), or systemic lupus erythematosus.
Patients wider than 55 cm across the chest/ shoulders/hips or weighing more than 134 kg exceeded the capacity of our MRI machine and thus were ineligible for the study. Those suering from claustrophobia or having free¯oating metal in their body (bullets, fragments in eye etc.) were also ineligible for MRI scanning. Because of budget constraints any potential subject requiring more than $500.00 (Can) in transportation reimbursement was not enrolled.
Ethical approval (C91-069 for this study) was obtained from The University of British Columbia Clinical Screening Committee for Research Involving Human Subjects, as well as separately from the University of Manitoba. All subjects provided informed consent. A retrospective chart review identi®ed eligible subjects who were then contacted by letter for participation in the prospective assessment for AVN.
A magnetic resonance imaging (MRI) scan of both humeral and both femoral heads was performed on each subject at a minimum of 6 months post-injury (mean 21.4, range 6 ± 46). The two radiologists evaluating the MRI scans were unaware of the treatment protocol received by the individual subject. Coronal and axial T1 weighted (TR800 TE20) and T2 weighted (TR2000 TE20/80) images were obtained. Throughout the study the radiologists reported their ®ndings by consensus.
Our population sample size requirements were based on extremely conservative AVN incident rate estimates of 2% in the control group and 10% in the treatment group, recognizing that there had been no prior report of the incidence of AVN in the spinal cord injured. By this criteria, 107 subjects were required in each group. Since most patients did not return to their pre-injury residence eorts to locate them included contacting next of kin (as recorded during hospital admission), family physicians, the Canadian Paraplegic Association, telephone services, rehabilitation services, and medical insurance services.
Results
Collecting the estimated 214 subjects was not possible due to poor patient compliance and lack of forwarding addresses. There were 508 potential subjects admitted to the ASCIU in Vancouver between December 1988 and June 1995. Of these, 253 met the inclusion criteria. We were unable to contact 82 of those eligible. Of the remainder only 62 agreed to enroll. The Winnipeg ASCIU enrolled 29 subjects all of whom were treated with high dose steroid protocols between July 1990 and August 1994. Budget constraints forced enrollment in the non-steroidal group to be closed contingent upon no case of AVN appearing to that time in the steroid group. (One patient was found to have AVN by MRI scan but, radiographic evidence revealed an older injury which the patient admitted having forgotten about; consequently, this patient was excluded from the study).
There were 32 spinal cord injured subjects (seven females, 25 males), aged 16 ± 65 years (mean 34 years) who did not receive steroids. There were 59 spinal cord injured (®ve females, 54 males), aged 15 ± 64 years (mean 32 years), who received the NASCIS-2 protocol.
Had a group with AVN been identi®ed, statistical analysis would have been dicult; however, there was no case of AVN found in either group. Therefore, using binomial distribution, the true incidence of AVN among the methylprednisolone treated group is predicted to be less than 5% (a50.05).
Discussion
Because of the results of the NASCIS-2 study we could not ethically withhold Mpred treatment from one group of subjects. Therefore, retrospective enrollment of controls was necessary. Upon release from hospital, the cord-injured people seldom returned to their preinjury residence because of their new needs for building access, assisted living, and transportation convenience. Once located, many potential subjects chose not to participate because they wanted no reminders of the incident and recover process that had so drastically changed their lives. Of those who agreed to participate, many later either reneged or failed to attend for the MRI scan. Even invitation to participate while in the rehabilitation hospital failed (this would have still allowed MR scanning to be done at about three months after treatment). Consequently it was at least twelve months post injury before any of these candidates were assessed.
After the initial reporting of the NASCIS-2 study, 5 nursing and pharmacy reports 6,18 described a formula for calculating the Mpred dosage which included an additional 2500 mg Mpred for priming the intravenous administration set. Our study attached the Mpred solution bag to an existing intravenous delivery; therefore, we used the protocol as initially published. 5 While there could be a dierence in the total amount of Mpred delivered by the two methods 5, 6, 18 we do not believe any consequent dierence in neurologic improvement would alter the clinical question of whether the neurological bene®t oset the risk of AVN. We felt that even a low incidence (e.g. 10%) of AVN would be unacceptable considering its impact on the mobility of the spinal cord injured and the notoriously poor outcome of its treatment measures.
Why was AVN not seen in these patients, despite the very high steroid dose? We suggest that the steroid eect is only seen where vasculitis has been triggered by an immune reaction (to a serum or a grafted organ, or in autoimmune disease). This explains the baseline incidence of AVN in a number of these conditions, and the absence after spinal cord injury. This suggests that the use of megadose steroid will be safe if of short duration. The use of megadose mpred in a recently cord-injured person in whom such immune processes already exist may carry the risk of AVN, a risk that should be discussed with the patient.
Since no evidence of AVN was found, the incidence rate predicted by our sample size is less than 5% (a50.05, with a power of 0.8), and we continue to recommend the use of the NASCIS-2 high dose methylprednisolone protocol, provided it is restricted to a 24 h period. The publication of the NASCIS-3 protocol suggesting that the methylprednisolone be continued for 48 h in certain patients is probably safe but a monitoring program may be required. 19 
